Tuesday, November 15, 2011

Aastrom Bioscience Reports Good News

Aastrom Biosciences (ASTM) is making forward progress, but financing remains a huge concern for many investors. Aastrom released the following yesterday on 02011.11.14: Aastrom Reports Positive 12-Month Results from the RESTORE-CLI Phase 2 Clinical Trial for Ixmyelocel-T in Patients with Critical Limb Ischemia

"We were one event [amputation] away from reaching statistical significance," says Aastrom CEO Tim Mayleben. [source: TheStreet.com]

Headline at TheStreet.com: "Aastrom Cell Therapy Reverses Effects of Blocked Leg Arteries".

The importance of a trail being statistically significant is significant.

ASTM on Monday, 02011.11.14. Previous close: $2.75; open $2.80; intra-day high $2.91; intra-day low $2.43; close $2.58. For the day ASTM was down 6.2%. Trading volume was 1,021,500 vs. trailing-3-month average of 262,702.

After the markets closed yesterday (02011.11.14), I saw Stem cells help regenerate damaged heart on the CBS Evening News. Nutshell: Stem cells generated by heart tissue help repair damaged heart.

"It's like someone gave me a magic pill," he said. "I felt better all over suddenly. It's science fiction basically to me. That's what it feels like." [source: CBSNews.com]

No comments:

Post a Comment